The Centers for Disease Control and Prevention defines health equity as “the state in which everyone has a fair and just opportunity to achieve their highest level of health.” The clinical trials industry stands at a precipice, buffeted by community and regulatory calls for diversity action plans and headlines that highlight health disparity statistics. With great opportunity to innovate and streamline clinical trial processes that have historically and currently preclude diverse participation and representation, we are called to answer core questions related to the role of health equity in clinical trial design. Whether observational or experimental, the clinical trials industry must realign its “why” with and through community engagement by being responsive to participation barriers that intersect with multiple levels of challenges posed by social drivers of health and cultural norms.
CEU: 1.00 ACRP
Speaker:
Gelise Thomas, JD, MS, Founder and CEO, HEIR Ventures LLC
Watch a Sneak Peek into the Session Content: